Lib­tayo, chemo com­bo clears lung can­cer tri­al two years ear­ly. But can it com­pete with Keytru­da?

With the sixth check­point in­hibitor on the US mar­ket, Re­gen­eron and Sanofi sought to cre­ate their own mar­ket for Lib­tayo by go­ing af­ter in­di­ca­tions oth­er drug­mak­ers hadn’t. That all changed in Feb­ru­ary when Lib­tayo scored an OK in non-small cell lung can­cer — the in­di­ca­tion that put Mer­ck’s Keytru­da on the map.

Now, the part­ners are look­ing to take on the heavy­weight champ in a chemother­a­py com­bi­na­tion for lung can­cer pa­tients with low­er PD-L1 ex­pres­sion, and they’re con­fi­dent they’ve got the da­ta to do it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.